CORRECTING OF ANEMIA USING IRON SUCROSE IN PATIENTS WITH CHRONIC KIDNEYDISEASE STAGE VD ON HEMODIALYSIS
Abstract
Anemia is a common complication of CKD. Iron deficiency is one of a leading cause of anemia in HD patients. The causes of iron deficiency in these patients are multifactorial. Main factors that contribute to iron deficiency in HD patients are reduction intake and impaired intestinal absorption of dietary iron, blood losses, chronic inflammation and increased iron requirements during therapy with erythropoiesis–stimulating agents.
Aim.The aim was to study efficacy and safety of iron sucrose (Venofer) in HD patients with anemia.
Materials and methods. This study was an retrospective, epidemiologic, performed from 2010 to 2014 years. The study included 69 HD patients with anemia from dialysis single–center. 38 (55.1%) patients were men, average age 49,53 ± 3,9years and the most common cause of ESRD was glomerulonephritis (37 patients, 53.6%). Hemoglobin value was analyzed weekly. The levels of serum ferritin and transferrin saturation, were determined before and after treatment with Venofer.
Results. Treatment with the Venofer resulted a significant increase of hematological and iron exchange parameters. At 2 – 3 weeks of therapy, hemoglobin levels increased by 7,6% and 10,7%, respectively. 14 days after the last dose Venoer serum ferritin and transferrin saturation levels have increased by 58% and 55%, respectively.
Conclusions. Intravenous iron is the preferred route of administration in HD patients. Venofer showing a significant increase both of hemoglobin and iron exchange markers levels on a background of insignificant frequency of treatment–related adverse events.
Downloads
References
Дудар І. О. Рівні прозапальних цитокінів (ІЛ–1Р, ФНП–а) у пацієнтів, які лікуються програмним гемодіалізом, залежно від ступеня анемії та характеру ураження нирок / І. О. Дудар [та ін.] // Український журнал нефрології та діалізу: матеріали науково–практичної конференції «Проблемні питання діагностики і лікування хвороб нирок», м. Луцьк, 11–12 жовтня 2012 р. – 2012. – Додаток №1 до № 3 (35). – С. 90–94.
Національний реєстр хворих на хронічну хворобу нирок: 2012 рік / уклад. Н.І. Козлюк [та ін.]; Академія медичних наук України, Мінистерство охорони здоров’я України, Державна установа “Інститут нефрології НАМН України”; гол. ред. М.О.Колесник. – К., 2013. – 89с.
Шіфріс І.М. Фактори, що сприяють розповсю– дженості бактеріальних інфекцій у гемодіалізній популяції / І. М. Шіфріс // Материалы научнопрактической конференции «Урология и нефрология: вчера, сегодня, завтра...», посвященной 45–летию Областного клинического центра урологии и нефрологии им. В.И. Шаповала, г. Харьков, 1–2 ноября, 2012 г. / Под ред. В.Н. Лессового, И.М. Антоняна – Харьков, 2012. – С. 202–203.
Arbor Research Collaborative for Health. DOPPS Practice Monitor, August 2013. Available at: http:// www.dopps.org/DPM/Default.asp.
Bailie G. R. Hypersensitivity reactions and deaths associated with intravenous iron preparations. / G. R. Bailie [et al.] // Nephrol Dial Transplant. – 2005. – Vol. 20. – P.1443–1449.
Besarab A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. / A. Besarab [et al.] // J. Am. Soc. Nephrol. – 2000. – Vol. 11 . – P. 530–538.
Chuang C. L. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high–fluorescence reticulocyte count in haemodialysis patients. / C. L. Chuang [et al.]. // Nephrol Dial Transplant. – 2003. – Vol. 18. – P. 370.– 377.
Chertow G. M. Update on adverse drug events associated with parenteral iron. / G. M. Chertow [et al.] // Nephrol Dial Transplant. – 2006. – Vol.21. – P.378–382.
Fishbane S. The evaluation of iron status in hemodialysis patients. / S. Fishbane [et al.] // J Am Soc Nephrol. – 1996. – Vol. 7. – P. 2654 –2657.
Fishbane S.: Iron supplementation in renal anemia. / S. Fishbane // Semin Nephrol. – 2006. – Vol. 26. – P. 319 –324.
Ganz T. Immunoassay for human serum hepcidin / T. Ganz, G.Olbina, D.Girelli // Blood. – 2008. – Vol. 112. – P. 4292–4297.
Goldberg L.A. Iron sucrose similars. / L.A. Goldberg. // Hosp Pharm Eur – 2010. – Vol. 48. – P. 21–22.
Horl W. Clinical aspects of iron use in the anemia of kidney disease / W. Horl // J. Am. Soc. Nephrol. – 2007. – Vol 18. – P 382–393.
Kalantar–Zadeh K, Rodriguez R.A., Humphreys M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. / K. Kalantar–Zadeh, R.A. Rodriguez, M.H. Humphreys // Nephrol Dial Transplant. – 2004. – Vol. 19. – P. 141 –149.
Kalantar–Zadeh K, Kalantar–Zadeh K, Lee G.H. The fascinating but deceptive ferritin:To measure it or not to measure it in chronic kidney disease? / K. Kalantar– Zadeh, K. Kalantar–Zadeh, G.H. Lee. // Clin J Am Soc Nephrol. – 2006. – Vol. 1. – P.9 –18.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. – 2012. – № 2. – Р. 279–335.
Piga A. Evaluation and treatment of secondary iron overload. In: Beaumont C, Beris P, Beuzard Y et al, eds. Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism. / A. Piga [et al.]. // European Society of Haematology Handbook. . – 2009. – P. 585–604.
Pisoni R.L. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). / R.L. Pisoni [et al.] // Am J Kidney Dis. – 2004. – Vol. 44 [Suppl 1]. – P. 94–111.
Rozen–Zvi B. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta–analysis. / B. Rozen–Zvi [et al.]. // Am J Kidney Dis. – 2008. – Vol.52. – P.897–906.
Shaldon S. Chronic dialysis without transfusion. / S. Shaldon. // Lancet. – 1967. – Vol. 1. – P. 783–784.
Schellekens U. The therapeutic equivalence of complex drugs. / U. Schellekens [et al.] // Regul Toxicol Pharmacol. – 2011. – Vol. 59. – P.176–183.
Toblli J.E. Diff erences between the original iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications. / J. E. Toblli [et al.]. // J Nephrol Hypert. – 2009. – Vol.23. – P.53–63
U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and EndStage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013. http: //www.usrds.org/atlas.aspx.
Weiner D. E., Winkelmayer W. C. Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle’: Iron(y) Abounds 2 Years Later / D. E. Weiner, W. C. Winkelmayer // American Journal of Kidney Diseases. – 2013. – Vol. 62. – P. 1217 – 1220.
Wish J.B. Assessing iron status: Beyond serum ferritin and transferrin saturation. / J.B. Wish. // Clin J Am Soc Nephrol. – 2006. – Vol. 1. – P.4 –8.
Young B. Hepcidin for clinicians. / B. Young, J. Zaritsky // Clin. J. Am. Soc. Nephrol. – 2009. – Vol. 4. – P. 1384–1387.
Zaritsky J. et al.Hepcidin – a potential novel biomarker for iron status in chronic kidney disease. / J. Zaritsky [et al.] // Clin. J. Am. Soc. Nephrol. – 2009. – Vol. 4. – P. 1051–1056.
